Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Yu. V. Gagarina"'
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 7 (2024)
Aim. To evaluate the dapagliflozin as part of various treatment regimens in patients with heart failure (HF) with reduced ejection fraction (HFrEF) ≤40% receiving medications within federal preferential drug program to achieve the "Reduction of car
Externí odkaz:
https://doaj.org/article/85abe79f5e0f450bb775afd8c166d43f
Publikováno v:
Российский кардиологический журнал, Vol 29, Iss 1 (2024)
Aim. To evaluate the contribution ticagrelor compared with clopidogrel therapy in patients with acute coronary syndrome (ACS) and patients with myocardial infarction (MI) to achieving the State Program "Health Development" target "decrease of cardiov
Externí odkaz:
https://doaj.org/article/6f8a679cd16942aeb89f3ce19fcda5b0
Publikováno v:
Фармакоэкономика, Vol 16, Iss 2, Pp 149-161 (2023)
Objective: to evaluate the pharmacoeconomic feasibility of using monoclonal antibodies or their combinations vs standard therapy in patients with mild and moderate-severe COVID-19 in order to prevent the severe course of the disease.Material and meth
Externí odkaz:
https://doaj.org/article/43881cff3b6f49d39ac43dfe61b89980
Publikováno v:
Российский кардиологический журнал, Vol 28, Iss 12 (2023)
Aim. To assess cost-effectiveness of valsartan+sakubitril, dapagliflosin and empagliflosin for prevention of cardiovascular death and achieving the target indicator "reduction of cardiovascular mortality" of the State Program "Health Development" in
Externí odkaz:
https://doaj.org/article/6cc458674a974f17a82f73f50ddf9db6
Publikováno v:
Фармакоэкономика, Vol 15, Iss 2, Pp 175-186 (2022)
Objective: evaluation of the pharmacoeconomic feasibility of using benralizumab in the form of autoinjector (pen-injector device) in outpatient facilities compared with its use in the form of a syringe in hospital settings for the treatment of severe
Externí odkaz:
https://doaj.org/article/72fcc46ddb5641bcb973d16bbf0fcb4d
Autor:
M. V. Zhuravleva, S. N. Tereshchenko, I. V. Zhirov, S. V. Nedogoda, Yu. V. Gagarina, E. A. Shabalina
Publikováno v:
Российский кардиологический журнал, Vol 28, Iss 3 (2023)
Aim. To evaluate the cost-effectiveness of achieving the target indicator "Reduction of the cardiovascular mortality of the population" of the State Program "Health Development" when using drugs valsartan+sacubitril, dapagliflozin and empagliflozin i
Externí odkaz:
https://doaj.org/article/f476d2a5aaba400aad79ebda1c3767bc
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 12 (2022)
Aim. To evaluate the effect of the use of the double antiplatelet therapy (DAT) with ticagrelor compared to DAT with clopidogrel and antithrombotic therapy with acetyl salicylic acid (ASA) in patients with acute coronary syndrome and patients with hi
Externí odkaz:
https://doaj.org/article/72881da139644a0e83c2f42ee1216121
Autor:
M. V. Zhuravleva, S. N. Tereshchenko, I. V. Zhirov, S. V. Villevalde, T. V. Marin, Yu. V. Gagarina
Publikováno v:
Российский кардиологический журнал, Vol 26, Iss 12 (2022)
Aim. To assess the effect of therapy with sodium glucose co-transporter type 2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction (CHrEF) on the state cardiovascular mortality target indicators.Material and methods.
Externí odkaz:
https://doaj.org/article/a6b33c8db5a540299968419bb86339f8
Publikováno v:
Российский кардиологический журнал, Vol 25, Iss 12 (2020)
Aim. To assess the additional effect of ticagrelor as part of dual antiplatelet therapy (DAPT) compared with DAPT with clopidogrel and acetylsalicylic acid (ASA) monotherapy on the achievement of goals of federal project on the prevention of cardiova
Externí odkaz:
https://doaj.org/article/4945bc6c5e5d46c5b46a903776d013e7
Autor:
M. V. Zhuravleva, S. N. Tereshchenko, I. V. Zhirov, S. V. Villevalde, T. V. Marin, Yu. V. Gagarina
Publikováno v:
Российский кардиологический журнал, Vol 25, Iss 10 (2020)
Aim. To assess the effect of dapagliflozin in patients with heart failure with reduced ejection fraction (HFrEF) on reducing cardiovascular mortality as the main goal of a federal project on the prevention of cardiovascular diseases.Material and meth
Externí odkaz:
https://doaj.org/article/b7da9ff18e4446f8989b8d6d0d051f99